Jnana Therapeutics is a drug discovery company focusing on small molecule therapies for phenylketonuria along with other immune related conditions.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
11/15/2022 | Series C-2 | $47MM | $xx.xx | $292.93MM | Bain Capital, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures | |
Price per Share
$xx.xx
Shares Outstanding
52,659,140
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
3.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Bain Capital, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures
|
||||||
11/15/2022 | Series C-1 | $60MM | $xx.xx | $292.93MM | Bain Capital, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures | |
Price per Share
$xx.xx
Shares Outstanding
94,114,208
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
3.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Bain Capital, RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, Pfizer Ventures
|
||||||
08/18/2021 | Series B | $50MM | $xx.xx | $175.22MM | RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, AbbVie Ventures, Pfizer Ventures | |
Price per Share
$xx.xx
Shares Outstanding
52,785,490
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
3.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures, AbbVie Ventures, Pfizer Ventures
|
||||||
12/14/2017 | Series A-1 | $17.25MM | $xx.xx | $134.9MM | Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures, Pfizer R&D Innovate | |
Price per Share
$xx.xx
Shares Outstanding
34,500,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
3.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures, Pfizer R&D Innovate
|
||||||
12/14/2017 | Series A | $32.95MM | $xx.xx | $134.9MM | Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures, Pfizer R&D Innovate | |
Price per Share
$xx.xx
Shares Outstanding
32,950,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
3.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Polaris Partners, Avalon Ventures, Versant Ventures, AbbVie Ventures, Pfizer R&D Innovate
|